Gaithersburg, MD, October 26, 2015 – MaxCyte®, Inc., 'the pioneer in cell therapies using scalable, high-performance cell transfection systems, today announces that Dr. James Brady, Vice President for Technical Applications and Customer Support, will present at the BioProcess International Conference to be held October 26-29 at the Hynes Convention Center in Boston, MA. Dr. Brady will give a presentation entitled “Rapid Production of Recombinant Proteins and Stable Cell Lines at Different Scales.” In the presentation, Dr. Brady will discuss how MaxCyte was able to achieve 2.7 g/L of antibody in CHO cells using MaxCyte’s Flow Electroporation coupled with cell culture optimization. In addition, the use of this technology to enable research and development with CHO cells for rapid clinical-grade biotherapeutics will be discussed.
“Achieving 2.7 grams/Liter in CHO cells is an extraordinary accomplishment using transient transfection,” said Dr. Brady, Vice President of Technical Applications and Customer Support. “Along with attaining high titers, no other transient transfection system has the scalability, flexibility regarding cell type, and the reproducibility as the MaxCyte Flow Electroporation Systems.”
Details of the MaxCyte presentation are as follows:
Event: BioProcess International
Title: Rapid Production of Recombinant Proteins and Stable Cell Lines at Different Scales
Date: Tuesday, October 27, 2015
Time: 11:50 am
Location: Hynes Convention Center, Boston, MA
Along with the podium presentation, MaxCyte will present a scientific poster and have an exhibit booth with the MaxCyte STX® Scalable Transfection System, the MaxCyte VLX® Large Scale Transfection System, and the MaxCyte GT Flow Electroporation System on display. The MaxCyte GT is currently being used in preclinical trials with several institutions for cell-based therapeutics to treat solid tumors. MaxCyte scientists will be available throughout the conference to provide technical details on the operation and use of the instruments for small molecule drug discovery, biotherapeutics, and cell-based medicines.
About MaxCyte
MaxCyte is the leader in driving the next generation of cell-based medicines with flow electroporation. MaxCyte’s best-in-class cell modification technology is used in the discovery, development, and manufacture of small molecule, biologic, and cell-based medicines. The MaxCyte GT® Flow Transfection System, the MaxCyte STX® Scalable Transfection System, and the MaxCyte VLX® Large Scale Transfection System enable the rapid development and consistent production of (co)transfected cells for cellular therapy, genetic engineering, protein and antibody production, rapid response vaccine development, and cell-based assays with comparable results and Seamless Scalability™ from the bench to HTS and pilot and production scale. In addition to being used in 9 out of the top 10 companies worldwide, MaxCyte currently has clinical, pre-clinical-partnered, and proprietary products under development and is involved in more than a dozen clinical trials.
For more information, http://www.maxcyte.com.
Help employers find you! Check out all the jobs and post your resume.
“Achieving 2.7 grams/Liter in CHO cells is an extraordinary accomplishment using transient transfection,” said Dr. Brady, Vice President of Technical Applications and Customer Support. “Along with attaining high titers, no other transient transfection system has the scalability, flexibility regarding cell type, and the reproducibility as the MaxCyte Flow Electroporation Systems.”
Details of the MaxCyte presentation are as follows:
Event: BioProcess International
Title: Rapid Production of Recombinant Proteins and Stable Cell Lines at Different Scales
Date: Tuesday, October 27, 2015
Time: 11:50 am
Location: Hynes Convention Center, Boston, MA
Along with the podium presentation, MaxCyte will present a scientific poster and have an exhibit booth with the MaxCyte STX® Scalable Transfection System, the MaxCyte VLX® Large Scale Transfection System, and the MaxCyte GT Flow Electroporation System on display. The MaxCyte GT is currently being used in preclinical trials with several institutions for cell-based therapeutics to treat solid tumors. MaxCyte scientists will be available throughout the conference to provide technical details on the operation and use of the instruments for small molecule drug discovery, biotherapeutics, and cell-based medicines.
About MaxCyte
MaxCyte is the leader in driving the next generation of cell-based medicines with flow electroporation. MaxCyte’s best-in-class cell modification technology is used in the discovery, development, and manufacture of small molecule, biologic, and cell-based medicines. The MaxCyte GT® Flow Transfection System, the MaxCyte STX® Scalable Transfection System, and the MaxCyte VLX® Large Scale Transfection System enable the rapid development and consistent production of (co)transfected cells for cellular therapy, genetic engineering, protein and antibody production, rapid response vaccine development, and cell-based assays with comparable results and Seamless Scalability™ from the bench to HTS and pilot and production scale. In addition to being used in 9 out of the top 10 companies worldwide, MaxCyte currently has clinical, pre-clinical-partnered, and proprietary products under development and is involved in more than a dozen clinical trials.
For more information, http://www.maxcyte.com.
Help employers find you! Check out all the jobs and post your resume.
